All In Biotech

Drug Trial Radar · NCT07436689

Long-Term Open-Label Extension Study of Oral Levosimendan

A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103)

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

800

Planned (sponsor's estimate)

Start

Mar 13, 2026

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Tenax Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) who received TNX-103 in a parent study.

Conditions

  • Pulmonary Hypertension Associated With HFpEF

Interventions

  • TNX-103Drug

    Open-label oral levosimendan 1-3mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEsTime frame: From enrollment through study completion (up to 3 years)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Tenax Investigational Site

    Chicago, Illinois

  • Tenax Investigational Site

    Boston, Massachusetts

  • Tenax Investigational Site

    Minneapolis, Minnesota

  • Tenax Investigational Site

    Rochester, Minnesota

  • Tenax Investigational Site

    St Louis, Missouri

  • Tenax Investigational Site

    Omaha, Nebraska

  • Tenax Investigational Site

    New York, New York

  • Tenax Investigational Site

    Durham, North Carolina

  • Tenax Investigational Site

    Charleston, South Carolina

  • Tenax Investigational Site

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.